For citations:

Kolyadina I.V. The role of ribociclib in the treatment of early hormone receptor-positive HER2-negative breast cancer: 4-year results of the randomized controlled phase 3 trial NATALEE and their reconsideration for clinical practice. Tumors of female reproductive system. 2025;21(2):47-59. (In Russ.) https://doi.org/10.17650/1994-4098-2025-21-2-47-59